Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?
For example, absolute benefit estimated from Oncotype DX reports